Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02240693 · ClinicalTrials.gov registry record · Phase 2
Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 128
- Enrollment target
NCT02240693 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 128 participants.
The verdict
NCT02240693, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 128 participants
- Enrollment target
Study Summary
The study is designed to compare the effects of 4 different doses of orally administered BI 409306 to placebo in patients with Alzheimers Disease
Interventions
- DRUG Placebo
- DRUG BI 409306
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2015-01-15 |
| Est. Completion | 2017-10-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02240693
The ClinicalTrials.gov registry entry for NCT02240693 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02240693 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02240693 about?
NCT02240693 is a clinical study titled "Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo". The study is designed to compare the effects of 4 different doses of orally administered BI 409306 to placebo in patients with Alzheimers Disease
What is the current status of trial NCT02240693?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 128 participants. The study started on 2015-01-15. Estimated completion is 2017-10-09.
What interventions are being tested in trial NCT02240693?
The interventions under investigation include: Placebo (DRUG), BI 409306 (DRUG).
Who is sponsoring clinical trial NCT02240693?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.